BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Novartis
McKesson
Cerilliant
Farmers Insurance
Boehringer Ingelheim
Cipla
Covington
Federal Trade Commission
US Department of Justice

Generated: January 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,815,889

« Back to Dashboard

Which drugs does patent 8,815,889 protect, and when does it expire?

Patent 8,815,889 protects CONTRAVE and is included in one NDA.

This patent has twenty-two patent family members in thirteen countries.
Summary for Patent: 8,815,889
Title:Compositions and methods for increasing insulin sensitivity
Abstract: Methods and compositions for treating a blood glucose condition involve identifying a suitable subject and administering an effective amount of a composition that contains one or more of an opioid antagonist, an anticonvulsant, and a psychotherapeutic agent. The compositions can include insulin. In some embodiments, such methods and compositions can be used to modulate a blood glucose level. In preferred embodiments, such methods and compositions are useful for increasing a subject's sensitivity to insulin.
Inventor(s): Cowley; Michael A. (Portland, OR), McKinney; Anthony A. (San Diego, CA), Tollefson; Gary (Indianapolis, IN)
Assignee: Orexigen Therapeutics, Inc. (San Diego, CA)
Application Number:11/602,571
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Dosage form;

Drugs Protected by US Patent 8,815,889

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Orexigen CONTRAVE bupropion hydrochloride; naltrexone hydrochloride TABLET, EXTENDED RELEASE;ORAL 200063-001 Sep 10, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe FOR EFFECT ON BLOOD GLUCOSE PARAMETERS IN PATIENTS WITH INSULIN RESISTANCE ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,815,889

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,457,005 Compositions and methods for increasing insulin sensitivity ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,815,889

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2630624 ➤ Subscribe
China 101370488 ➤ Subscribe
Denmark 2135603 ➤ Subscribe
European Patent Office 1951212 ➤ Subscribe
European Patent Office 2292220 ➤ Subscribe
European Patent Office 2135603 ➤ Subscribe
European Patent Office 3132792 ➤ Subscribe
Spain 2402522 ➤ Subscribe
Japan 2009516744 ➤ Subscribe
Japan 5180092 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
AstraZeneca
Harvard Business School
Farmers Insurance
Chinese Patent Office
Cerilliant
Daiichi Sankyo
Mallinckrodt
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot